Medincell's partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and ...
Teva presented positive Phase 3 SOLARIS trial results for Olanzapine LAI, showing significant improvements in social functioning and quality of life in schizophrenia patients, with no PDSS events. Real-world data on UZEDY revealed high adherence rates among socially vulnerable schizophrenia patients.
Medincell's Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal
Teva presented positive Phase 3 SOLARIS trial results for Olanzapine LAI in schizophrenia at ECNP 2024, showing efficacy, safety, and tolerability across three doses, with no new safety signals or cases of PDSS.
© Copyright 2024. All Rights Reserved by MedPath